Takeda and idt support manufacturing of johnson & johnson's covid-19 vaccine

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced a mutual agreement with idt biologika gmbh (“idt”), a contract development and manufacturing organization, to utilize capacity at idt previously reserved for takeda's dengue vaccine candidate (tak-003) to manufacture the single-shot covid-19 vaccine developed by the janssen pharmaceutical companies of johnson & johnson. at the end of a three-month period, the capacity will be
TAK Ratings Summary
TAK Quant Ranking